(4-68)	AIC ENERGY COMMISSION	Form Approved Budget Bureau No.
	RTIFICATE—IN VITRO TESTING ATERIAL UNDER GENERAL LICENSE	38–R0160
Section 31.11 of 10 CFR 31 establishes a general license au quantities of byproduct material for <i>in vitro</i> clinical or lab material or the radiation therefrom to human beings or anim the physician, clinical laboratory, or hospital has filed Form	poratory tests not involving the internal or external administration nais. Possession of byproduct material under 10 CFR 31.11 i	s not authorized until
with registration number.	INSTRUCTIONS	
unbmit this form in triplicate to: United States Atomic Ene Materials Licensing. A registration number will be assigned	ergy Commission, Washington, D.C. 20545, Attent	tion: Director, Division of turned.
1. Please print or type within the shaded area, below, the nar tory, or hospital for whom or for which this registration for		nt physician, clinical labora-
William O Umiliam N.D.		
William O. Umiker, M.D. Director of Clinical Laborat	tory	
St. Joseph Hospital		
Lancaster, Penna, 17604		
	3. To be completed by the Atomic Energy Commi	ssion
2. I hereby apply for a registration number pursuant to	Registration number:	1061
§ 31.11, 10 CFR 31 for use of byproduct materials for	U. S. ATOMIC ENERGY COMPLESS	EON
(please check one):		
<ul> <li>a. Myself, a duly licensed physician authorized to dis- pense drugs in the practice of medicine.</li> </ul>		
b. The above-named clinical laboratory.		
c. The above-named hospital.	BY: Clarence A. Hebron	Aug. 17 1971
	BY: CLERGTOG Spate Blanden to be as	igned by GLEC) 1 1 1 1971
5. Certification:		
I hereby certify that:		
a. All information in this registration certificate is true a	and complete.	
b. The registrant has appropriate radiation measuring inst the general license of 10 CFR 31.11. The tests will be pe handling of the byproduct materials.	truments to carry out the tests for which byproduct erformed only by personnel competent in the use of	material will be used under the instruments and in the
c. I understand that Commission regulations require that a icate be reported to the Director, Division of Materials L	Licensing, within 30 days from the effective date of suc	ch change.
d. I have read and understand the provisions of Section 31.1 and I understand that the registrant is required to compl possesses, uses, or transfers under the general license for	ly with those provisions as to all byproduct material	which he receives, acquire
July 29, 10071	P.,	
	By Signature of person filin	g form
<u>VI-O. Uniker, M.D., Director of Cl</u> Printed name and title or position of person filing form	linical Laboratory	
WARNING.—18 U.S.C., Section 1001; Act of June 25, 1948; 62 sentation to any department or agency	Stat. 749; makes it a criminal offense to make a willfully of the United States as to any matter within its jurisdictio	false statement or repre- n.
WARNING.—18 U.S.C., Section 1001; Act of June 25, 1948; 62 sentation to any department or agency	Stat. 749; makes it a criminal offense to make a willfully of the United States as to any matter within its jurisdictio	false statement or repre- n.
WARNING.—18 U.S.C., Section 1001; Act of June 25, 1948; 62 sentation to any department or agency	Stat. 749; makes it a criminal offense to make a willfully of the United States as to any matter within its jurisdictio	false statement or repre- n.

•

## § 31.11 General license for use of iodine-125 or iodine-131 for in vitro clinical or laboratory testing.

(a) A general license is hereby issued to any physician, clinical laboratory, or hospital to receive, acquire, possess, transfer or use, for any of the following stated tests, in accordance with the provisions of paragraphs (b), (c), (d), (e), and (f) of this section, the following byproduct materials in prepackaged units:

(1) Iodine-125, in units not exceeding 10 microcuries each for use in in vitro clinical or laboratory tests not involving internal or external administration of byproduct material, or the radiation therefrom, to human beings or animals.

(2) Iodine-131, in units not exceeding 10 microcuries each for use in in vitro clinical or laboratory tests not involving internal or external administration of byproduct material, or the radiation therefrom, to human beings or animals.

(b) No person shall receive, acquire, possess, use or transfer byproduct material pursuant to the general license established by paragraph (a) of this section until he has filed Form AEC-483, "Registration Certificate—In Vitro Testing with Byproduct Material Under General License", with the Director, Division of Materials Licensing, U.S. Atomic Energy Commission, Washington, D.C. 20545, and received from the Commission a validated copy of Form AEC-483 with registration number assigned. The registrant shall furnish on Form AEC-483 the following information and such other information as may be required by that form:

Name and address of the registrant;
 The location of use; and

(3) A statement that the registrant has appropriate radiation measuring instruments to carry out in vitro clinical or laboratory tests

with byproduct materials as authorized under the general license in paragraph (a) of this section, and that such tests will be performed only by personnel competent in the use of such instruments and in the handling of the byproduct materials.

(c) A person who receives, acquires, possesses or uses byproduct material pursuant to the general license established by paragraph (a) of this section shall comply with the following:

(1) The general licensee shall not possess at any one time, pursuant to the general license in paragraph (a) of this section, at any one location of storage or use a total amount of iodine-125 and/or iodine-131 in excess of 200 microcuries.

(2) The general licensee shall store the byproduct material, until used, in the original shipping container or in a container providing equivalent radiation protection.

(3) The general licensee shall use the byproduct material only for the uses authorized by paragraph (a) of this section.

(4) The general licensee shall not transfer the byproduct material to a person who is not authorized to receive it pursuant to a license issued by the Commission or an Agreement State, nor transfer the byproduct material in any manner other than in the unopened, labeled shipping container as received from the supplier.

(d) The general licensee shall not receive, acquire, possess, or use byproduct material pursuant to paragraph (a) of this section:

(1) Except as prepackaged units which are labeled in accordance with the provisions of a specific license issued under the provisions of

<sup>1</sup> A State to which the Commission has transferred certain regulatory authority over radioactive material by formal agreement, pursuant to section 274 of the Atomic Energy Act of 1954, as amended. § 32.71 of this chapter or in accordance with provisions of a specific license issued by Agreement State, which authorizes manufacture and distribution of iodine-125 or iodine-131 for distribution to persons generally licensed by the Agreement State.

(2) Unless the following statement, or a substantially similar statement which contains the information called for in the following statement, appears on a label affixed to each prepackaged unit or appears in a leaflet or brochure which accompanies the package:

This radioactive material may be received, acquired, possessed, and used only by physicians, clinical laboratories or hospitals and only for in vitro clinical or laboratory tests not involving internal or external administration of the material or the radiation therefrom to human beings or animals. Its receipt, acquisition, possession, use, and transfer are subject to the regulations and a general license of the U.S. Atomic Energy Commission or of a State with which the Commission has entered into an agreement for the the exercise of regulatory authority.

## Name of manufacturer

(e) The registrant possessing or using byproduct materials under the general license of paragraph (a) of this section shall report in writing to the Director, Division of Materials Licensing, any changes in the information furnished by him in the "Registration Certificate-In Vitro Testing with Byproduct Material Under General License", Form AEC-483. The report shall be furnished within 30 days after the effective date of such change.

(f) Any person using byproduct mipursuant to the general license of paral.
(a) of this section is exempt from the requirements of Part 20 of this chapter with resp.
to byproduct materials covered by that general license.

## NOTE

If larger quantities or other forms of byproduct material than those specified in the general license of 10 CFR 31.11 are required, an "Application for Byproduct Material License," Form AEC-313, should be filed to obtain a specific byproduct material license. Copies of application and registration forms may be obtained from the United States Atomic Energy Commission, Washington, D.C. 20545, Attention: Isotopes Branch, Division of Materials Licensing.

## U.S. GOVERNMENT PRINTING OFFICE : 1968-0-320-651

AL IF WA IT OUN ITS!

DEVENTED